Stock comparison
CONMED
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
CNMD
CONMED
Market cap
$1.12B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | CNMD | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 45D | 65C | GMAB |
| Benjamin Graham | 36D | 64C | GMAB |
| Philip Fisher | 34F | 48D | GMAB |
| Peter Lynch | 21F | 25F | GMAB |
| Joel Greenblatt | 24F | 76B | GMAB |
| Charlie Munger | 41D | 68C | GMAB |
| Terry Smith | 36D | 71C | GMAB |
Side-by-side metrics
| Metric | CNMD | GMAB |
|---|---|---|
| Market cap | $1.12B | $16.5B |
| P/E (TTM) | 19.6x | 6.2x |
| EV/EBIT | 13.4x | 12.0x |
| ROIC (TTM) | 5.08% | 43.78% |
| Gross margin | 53.58% | 93.88% |
| Net margin | 4.0% | 18.23% |
| Revenue CAGR 5y | 7.99% | -18.45% |
| EPS CAGR 5y | -8.2% | -23.48% |
| Debt / Equity | 0.8x | 0.1x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
CNMD leads on
- Revenue CAGR 5y7.99%vs -18.45%+143%
- Dividend yield1.14%vs 0.0%+100%
- EPS CAGR 5y-8.2%vs -23.48%+65%
GMAB leads on
- Market cap$16.5Bvs $1.12B+93%
- Debt / Equity0.1xvs 0.8x+91%
- ROIC (TTM)43.78%vs 5.08%+88%
- Net margin18.23%vs 4.0%+78%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.